Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01687387 | Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) | PHASE2 | COMPLETED | 152 | — | — | Oct 1, 2012 | Nov 17, 2016 | Feb 8, 2019 | 43 | France |
| Arm | Type | Description |
|---|---|---|
| IPH2102 at 1 mg/kg | EXPERIMENTAL | lirilumab (IPH2102/BMS986015) at 1 mg/kg |
| IPH2102 at 0.1 mg/kg | EXPERIMENTAL | lirilumab (IPH2102/BMS986015) at 0.1 mg/kg |
| Placebo (Normal saline solution) | PLACEBO_COMPARATOR | Normal saline solution |
| Name | Type | Description |
|---|---|---|
| IPH2102 at 0.1 mg/kg | DRUG | every 3 months |
| IPH2102 at 1 mg/kg | DRUG | every 4 weeks |
| Placebo (normal saline solution) | DRUG | every 4 weeks |
Inclusion Criteria: 1. Primary or secondary Acute Myeloid Leukemia (AML, defined according to WHO 2008 criteria), in first CR/CRi (according to the revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Stand...